CryoPort, Inc. (CYRX) - What Are Investment Firms Saying About This Stock?

Key Points

• Analysts are moderately bullish: Eight of ten brokerages rate CryoPort a buy, while two recommend holding the stock. The average 12-month price target is $19.33, above its $16.23 opening price.
• Institutional ownership is high: Institutional investors own 92.9% of CryoPort, with several funds recently initiating positions. CEO Jerrell Shelton sold 28,800 shares under a pre-arranged trading plan, reducing his stake by 2.34%.
• Financial performance remains challenged: CryoPort slightly missed quarterly EPS expectations, reporting a $0.20 loss per share, despite revenue exceeding estimates. Analysts expect a full-year loss of $0.83 per share.

CryoPort, Inc. (NASDAQ:CYRX - Get Free Report) has received an average rating of "Moderate Buy" from the ten brokerages that are presently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $19.33.

Several equities research analysts recently weighed in on CYRX shares. BTIG Research raised their price objective on CryoPort from $25.00 to $26.00 and gave the company a "buy" rating in a report on Tuesday, October 13th. Robert W. Baird set a $26.00 target price on CryoPort in a report on Tuesday, October 13th. Guggenheim lifted their price target on CryoPort from $16.00 to $19.00 and gave the company a "buy" rating in a research note on Thursday, October 1st. Needham & Company LLC boosted their price target on CryoPort from $15.00 to $19.00 and gave the stock a "buy" rating in a report on Friday, August 7th. Finally, Piper Sandler raised CryoPort to a "buy" rating in a research note on Tuesday, October 13th.

Insider Buying and Selling

In other CryoPort news, CEO Jerrell Shelton sold 28,800 shares of the business's stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $14.91, for a total transaction of $429,408.00. Following the sale, the chief executive officer directly owned 1,201,814 shares of the company's stock, valued at $17,919,046.74. The trade was a 2.34% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On CryoPort

Large investors have recently modified their holdings of the business. State of Alaska Department of Revenue bought a new stake in shares of CryoPort in the third quarter worth $40,000. State of Wyoming acquired a new stake in CryoPort in the third quarter valued at $81,000. Highland Investment Advisors LLC bought a new position in CryoPort during the 2nd quarter worth $306,000. Counterpoint Mutual Funds LLC bought a new position in CryoPort during the 3rd quarter worth $324,000. Finally, Kerrisdale Advisers LLC bought a new position in CryoPort during the 2nd quarter worth $355,000. Institutional investors own 92.90% of the company's stock.

CryoPort Price Performance

Shares of NASDAQ:CYRX opened at $16.23 on Tuesday. CryoPort has a one year low of $7.61 and a one year high of $18.88. The company has a market cap of $822.05 million, a price-to-earnings ratio of -18.03 and a beta of 1.96. The firm has a 50 day simple moving average of $16.94 and a 200 day simple moving average of $13.34.

CryoPort (NASDAQ:CYRX - Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($0.20) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.01). The company had revenue of $48.97 million for the quarter, compared to the consensus estimate of $48.18 million. CryoPort had a negative return on equity of 7.20% and a negative net margin of 20.05%. As a group, analysts expect that CryoPort will post -0.83 EPS for the current year.

CryoPort Company Profile

CryoPort, Inc NASDAQ: CYRX provides temperature-controlled supply chain solutions for the life sciences industry. The company supports the transportation, storage and management of biological materials, including cell and gene therapies, vaccines, biologics, reproductive materials and other temperature-sensitive products.

Its offerings include cryogenic and refrigerated shipping containers, biological material storage, transportation logistics, shipment monitoring and related supply chain management services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.